The company's proprietary protein-engineering platform produces targeted therapeutics that can coat implants and devices to achieve hyper-local delivery over long time periods.
Pooled 3-year outcomes from Intracept procedures demonstrate long-term pain relief and reduced opioid use in chronic vertebrogenic low back pain patients.
This customized surgery planning software, co-developed with NuVasive, is based on SMAIO's Balance Analyzer 3D vertebral realignment planning technology.